According to the Qichacha app, AstraZeneca CICC (Qingdao) venture capital fund partnership (limited partnership) was established with a capital of 1 billion yuan, with business scope including equity investment, investment management, asset management and other activities through private equity funds. According to the shareholding structure revealed by Qichacha, the company is jointly held by Wuxi AstraZeneca CICC venture capital partnership (limited partnership), Baoyang Pharmaceutical (301015) and others.
百洋医药等于青岛投资成立创投基金，出资额10亿元
Baoyang Pharmaceutical and Qingdao Investment have established a venture capital fund with a contribution amount of 1 billion yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.